Pharmacy Search
Pharmacy Pharmacy
Most Read Articles
Obesity not a reason for aggressive levofloxacin dosing for febrile neutropaenia prophylaxis
04 Oct 2020
Obesity does not appear to be strongly correlated with an increased risk for febrile neutropaenia during levofloxacin prophylaxis in patients with haematological malignancies receiving intermediate-risk myelosuppressive chemotherapy, suggests a study.
BICSTaR suggests efficacy of start/switch to bictegravir/emtricitabine/TAF in PLHIV
Roshini Claire Anthony, 25 Nov 2020

Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.

Corticosteroids show promise in paediatric DRESS
09 Nov 2020
Use of corticosteroids appears to be an effective treatment for paediatric drug reaction with eosinophilia and systemic symptoms (DRESS), suggest the results of a recent study. In severe cases, corticosteroids used in conjunction with intravenous immunoglobulin result in fast clinical improvement.
Chlorhexidine oral rinse improves COPD symptoms
Stephen Padilla, 10 Nov 2020
Patients with chronic obstructive pulmonary disease (COPD) seem to benefit from using chlorhexidine oral rinses twice daily as shown by the reduction in oral and sputum microbiota alpha diversity and by clinically significant improvements in COPD symptoms, according to a study presented at ID Week 2020.

Product Highlight - GALVUS MET

16 Sep 2020

As demonstrated by VERIFY study:

  • Early combination treatment strategy of Galvus Met was superior to standard of care metformin monotherapy: Offers 2 extra years of glycemic control1
  • Hypoglycemia and adverse event were not significantly increased with early initiation of Galvus Met vs metformin monotherapy1
  • Endorsed by ADA 2020 Guideline: Early treatment combination therapy can be considered at treatment initiation to extend the time to treatment failure in some patients2

 
References:
1) Matthews DR et al. Lancet. 2019;394:1519-1529;
2) American Diabetes Association. (2020). 7. Diabetes Technology: Standards of Medical Care in Diabetes-2020.Diabetes Care,43(Supplement 1), S77-S88.
3) Prescribing information available at https://www.novartis.com.my/product-list-v2/products?sort_bef_combine=title+ASC&sort_bef_combine=title+ASC&combine=galvus+met

Related MIMS Drugs

GALVUS MET
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Obesity not a reason for aggressive levofloxacin dosing for febrile neutropaenia prophylaxis
04 Oct 2020
Obesity does not appear to be strongly correlated with an increased risk for febrile neutropaenia during levofloxacin prophylaxis in patients with haematological malignancies receiving intermediate-risk myelosuppressive chemotherapy, suggests a study.
BICSTaR suggests efficacy of start/switch to bictegravir/emtricitabine/TAF in PLHIV
Roshini Claire Anthony, 25 Nov 2020

Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.

Corticosteroids show promise in paediatric DRESS
09 Nov 2020
Use of corticosteroids appears to be an effective treatment for paediatric drug reaction with eosinophilia and systemic symptoms (DRESS), suggest the results of a recent study. In severe cases, corticosteroids used in conjunction with intravenous immunoglobulin result in fast clinical improvement.
Chlorhexidine oral rinse improves COPD symptoms
Stephen Padilla, 10 Nov 2020
Patients with chronic obstructive pulmonary disease (COPD) seem to benefit from using chlorhexidine oral rinses twice daily as shown by the reduction in oral and sputum microbiota alpha diversity and by clinically significant improvements in COPD symptoms, according to a study presented at ID Week 2020.